Shehzad Jinnah
Internal Medicine · Eugene, ORNPI 1396734042
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 224 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 14.9% — the pattern of someone who eats at a lot of different presentations. Among internal medicine clinicians in OR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 224 payments — averaging $18.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$622
- AbbVie$481
- Pfizer$472
- Amarin Pharma, Inc.$425
- Amgen$323
- AstraZeneca$300
- plus $2K from 26 others
What the payments were for
- Food & beverage$4,15699%
- Education$301%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 38 | $622 |
| AbbVie | 29 | $481 |
| Pfizer | 26 | $472 |
| Amarin Pharma, Inc. | 30 | $425 |
| Amgen | 15 | $323 |
| AstraZeneca | 14 | $300 |
| Exact Sciences | 13 | $259 |
| Novo Nordisk | 11 | $187 |
| Boehringer Ingelheim | 7 | $179 |
| Boston Scientific | 1 | $142 |
| Bayer | 7 | $124 |
| Johnson & Johnson | 4 | $98 |
| Otsuka America Pharmaceutical, Inc. | 4 | $73 |
| Novartis | 3 | $58 |
| Sanofi-aventis U.S. LLC | 2 | $52 |
| Phathom Pharmaceuticals, Inc. | 2 | $45 |
| Heartflow, Inc. | 2 | $43 |
| Medicure Pharma Inc. | 1 | $40 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $33 |
| Regeneron Healthcare Solutions, Inc. | 1 | $24 |
| Aimmune Therapeutics, Inc. | 1 | $23 |
| Axsome Therapeutics, Inc. | 1 | $22 |
| Eisai Inc. | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| GSK | 1 | $18 |
| Gilead | 1 | $17 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $16 |
| Biohaven Pharmaceuticals, Inc. | 1 | $15 |
| Zealand Pharma US, Inc. | 1 | $15 |
| Bristol Myers Squibb | 1 | $15 |
| Philips North America LLC | 1 | $14 |
| Astellas Pharma US Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,186 in reported general payments places this provider in the 95th percentile of 1,363 internal medicine providers in Oregon.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 149 | $169,869 |
| MounjaroTirzepatide | 55 | $76,584 |
| OzempicSemaglutide | 38 | $44,890 |
| MyrbetriqMirabegron | 39 | $29,940 |
| JardianceEmpagliflozin | 16 | $23,799 |
| XareltoRivaroxaban | 18 | $15,046 |
| KerendiaFinerenone | 12 | $12,293 |
| Repatha SureclickEvolocumab | 12 | $6,711 |
| Celecoxib | 176 | $5,125 |
| Atorvastatin Calcium | 248 | $3,373 |
| Ramelteon | 18 | $3,358 |
| Cinacalcet Hcl | 14 | $3,207 |
| Rosuvastatin Calcium | 174 | $2,898 |
| SynthroidLevothyroxine Sodium | 23 | $2,672 |
| Metoprolol Succinate | 123 | $2,315 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $472 | $169,869149 claims |
| Lilly USA, LLCMounjaro | $622 | $76,58455 claims |
| Novo NordiskOzempic | $187 | $44,89038 claims |
| Astellas Pharma US IncMyrbetriq | $13 | $29,94039 claims |
| Boehringer IngelheimJardiance | $179 | $23,79916 claims |
| Johnson & JohnsonXarelto | $98 | $15,04618 claims |
| BayerKerendia | $124 | $12,29312 claims |
| AbbVieSynthroid | $481 | $2,67223 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,363 internal medicine providers in Oregon.
Other internal medicine in Eugene
- Marc UemuraEugene$20K
- Kirk JacobsonEugene$6K
- Chad PfeferBeaverton$639K
- Pranav ChandrashekarPortland$81K
- Jonathan EdmistonBend$68K
- Jessica CastlePortland$66K
- Ellen Schiaffino PurvisGresham$66K
- Steven ShawWhite City$58K
- Stephen SpurgeonPortland$42K
- Jane BabiarzPortland$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.